Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ribo-Life-EMA

More Like This

PR Newswire associated0

Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

PR Newswire associated0

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

PR Newswire associated0

Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs

PR Newswire associated0

Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange

PR Newswire associated0

U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity

PR Newswire associated0

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

PR Newswire associated0

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development